MEREO BIOPHARMA (MREO)
(Real Time Quote from BATS)
$1.60 USD
-0.03 (-1.84%)
Updated Aug 6, 2025 01:30 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MREO 1.60 -0.03(-1.84%)
Will MREO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MREO
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
Trump declares 50% tariff on copper, Brazil: Morning Buzz
US Stocks Mixed; Initial Jobless Claims Fall